ClinVar Miner

Submissions for variant NM_000090.4(COL3A1):c.3302G>C (p.Gly1101Ala)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
All of Us Research Program, National Institutes of Health RCV004805900 SCV005427370 likely pathogenic Ehlers-Danlos syndrome, type 4 2024-09-09 criteria provided, single submitter clinical testing The c.3302G>C (p.Gly1101Ala) variant in COL3A1 gene that encodes for collagen type III alpha 1 chain, has not been reported in individuals affected with Ehlers-Danlos syndrome or other COL3A1-related phenotypes. Changes to glycine residues of the COL3A1 protein are significantly enriched in individuals with COL3A1-related conditions (PMID: 24922459, 25758994). Glycine residues within the Gly-X-Y repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In-silico computational prediction tools suggest that the p.Gly1101Ala variant may have deleterious effect on the protein function (REVEL score: 0.937). This variant is absent in the general population database gnomAD (v4.1.0). Other variants at the same amino acid position, p.Gly1101Glu and p.Gly1101Arg, have been interpreted as pathogenic by ClinVar submitters (ClinVar ID: 101126, 17226). Therefore, the c.3302G>C (p.Gly1101Ala) variant in COL3A1 is classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.